BR112022009716A2 - Dosagem de um inibidor de tirosina quinase de bruton - Google Patents

Dosagem de um inibidor de tirosina quinase de bruton

Info

Publication number
BR112022009716A2
BR112022009716A2 BR112022009716A BR112022009716A BR112022009716A2 BR 112022009716 A2 BR112022009716 A2 BR 112022009716A2 BR 112022009716 A BR112022009716 A BR 112022009716A BR 112022009716 A BR112022009716 A BR 112022009716A BR 112022009716 A2 BR112022009716 A2 BR 112022009716A2
Authority
BR
Brazil
Prior art keywords
dosage
tyrosine kinase
kinase inhibitor
bruton tyrosine
bruton
Prior art date
Application number
BR112022009716A
Other languages
English (en)
Portuguese (pt)
Inventor
Jean Brandhuber Barbara
Chien Yee Ku Nora
Nanda Nisha
August Smith Steven
Tsai Donald
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of BR112022009716A2 publication Critical patent/BR112022009716A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022009716A 2019-12-06 2020-12-03 Dosagem de um inibidor de tirosina quinase de bruton BR112022009716A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962944674P 2019-12-06 2019-12-06
US202063077996P 2020-09-14 2020-09-14
US202063109698P 2020-11-04 2020-11-04
PCT/US2020/063089 WO2021113497A1 (en) 2019-12-06 2020-12-03 Dosing of a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
BR112022009716A2 true BR112022009716A2 (pt) 2022-08-09

Family

ID=73854977

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009716A BR112022009716A2 (pt) 2019-12-06 2020-12-03 Dosagem de um inibidor de tirosina quinase de bruton

Country Status (10)

Country Link
US (1) US12551463B2 (cg-RX-API-DMAC7.html)
EP (1) EP4069219A1 (cg-RX-API-DMAC7.html)
JP (3) JP7142173B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220100992A (cg-RX-API-DMAC7.html)
CN (1) CN115175677A (cg-RX-API-DMAC7.html)
AU (2) AU2020397034B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022009716A2 (cg-RX-API-DMAC7.html)
IL (1) IL292882B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006631A (cg-RX-API-DMAC7.html)
WO (1) WO2021113497A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3108065C (en) 2018-07-31 2025-10-07 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
KR20220100992A (ko) * 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US20150291554A1 (en) 2012-11-02 2015-10-15 Pfizer Inc. Bruton's Tyrosine Kinase Inhibitors
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
CN114605327B (zh) * 2015-12-16 2025-03-11 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
KR102376764B1 (ko) 2016-08-05 2022-03-18 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물
CN110177788B (zh) 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
SI3612531T1 (sl) 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva, ki sprožajo apoptozo
JP2020528061A (ja) 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
CN112437772B (zh) 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2抑制剂
CA3108065C (en) 2018-07-31 2025-10-07 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
KR20220100992A (ko) * 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여

Also Published As

Publication number Publication date
EP4069219A1 (en) 2022-10-12
KR20230127372A (ko) 2023-08-31
CN115175677A (zh) 2022-10-11
AU2024201263B2 (en) 2025-05-01
JP2022177119A (ja) 2022-11-30
IL292882B1 (en) 2026-05-01
US12551463B2 (en) 2026-02-17
AU2020397034A1 (en) 2022-07-21
AU2024201263A1 (en) 2024-03-14
IL292882A (en) 2022-07-01
JP2025098099A (ja) 2025-07-01
NZ788615A (en) 2024-10-25
CA3160417A1 (en) 2021-06-10
US20230041515A1 (en) 2023-02-09
MX2022006631A (es) 2022-09-07
AU2020397034B2 (en) 2023-12-07
JP7142173B2 (ja) 2022-09-26
JP7654604B2 (ja) 2025-04-01
KR20220100992A (ko) 2022-07-18
WO2021113497A1 (en) 2021-06-10
JP2022518974A (ja) 2022-03-17

Similar Documents

Publication Publication Date Title
NZ777871A (en) Small molecule modulators of il-17
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
EA202092154A1 (ru) Комбинированная терапия
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
JOP20210259A1 (ar) مستقبل استروجين يحلل خمير يستهدف التحلل البروتيني
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
BR112016008016B8 (pt) Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditos compostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ou nras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dos ditos compostos
EA201992329A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
PH12019500025A1 (en) Cancer treatment combinations
EA201992334A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
TN2018000218A1 (en) Indole carboxamides compounds useful as kinase inhibitors.
EA201992784A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
BR112021023110A2 (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
BR112021026369A2 (pt) Derivados de 2h-indazol e seu uso no tratamento de doenças
BR112021021826A8 (pt) Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
BR112021022602A2 (pt) Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]